OncoTherapy Science, Inc.
Biopharmaceutical company researching and developing novel anti-cancer therapies.
4564 | T
Overview
Corporate Details
- ISIN(s):
- JP3202150003
- LEI:
- Country:
- Japan
- Address:
- 川崎市川崎区東田町１番地２
Description
OncoTherapy Science, Inc. is a biopharmaceutical company focused on the research and development of novel anti-cancer therapies. The company utilizes cancer-specific gene data and comprehensive cancer genome analysis to discover and develop molecular-targeted drugs, antibody drugs, cancer vaccines, and new immunotherapies. Its key technological focuses include liquid biopsy, neoantigen prediction, and T-cell receptor (TCR) repertoire analysis using next-generation sequencing. The company's primary objective is to develop highly effective cancer treatments with minimal adverse events and side effects for patients.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2016-08-01 02:19 |
四半期報告書－第16期第1四半期(2016/04/01－2016/06/30)
|
Japanese | 189.4 KB | ||
| 2016-06-21 06:47 |
有価証券報告書－第15期(2015/04/01－2016/03/31)
|
Japanese | 963.7 KB | ||
| 2016-02-01 01:22 |
四半期報告書－第15期第3四半期(2015/10/01－2015/12/31)
|
Japanese | 203.3 KB | ||
| 2015-11-02 01:31 |
四半期報告書－第15期第2四半期(2015/07/01－2015/09/30)
|
Japanese | 236.4 KB |
Automate Your Workflow. Get a real-time feed of all OncoTherapy Science, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for OncoTherapy Science, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for OncoTherapy Science, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
